Vaccination against HPV-Associated Neoplasias

Neoplasias associated with anogenital human papilloma viruses (HPV) are characterised by high patient morbidity and mortality and by appreciable limitations in the patientʼs quality of life. Each year 530,000 women worldwide and 4800 women in Germany develop cervical cancer 1, 2. Biomolecular and epidemiological studies carried out in the past 25 years have demonstrated causal link between persisting infections with HPV 16 and HPV 18 and at least 11 other so-called high-risk HPVs (HR-HPVs) and the development of cervical cancer and its precursor lesions (so-called dysplasias or, respectively, cervical intraepithelial neoplasias – CIN). HPV 16, HPV 18 and other HR-HPVs are also the causes of…

Impfprävention HPV-assoziierter Neoplasien : Empfehlungen aus der aktuellen S3-Leitlinie des HPV-Management-Forums der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. – AWMF Leitlinien-Register Nr. 082-002 (Kurzfassung), gültig bis 31.12.2018